On November 8, 2021 Light Chain Bioscience reported to have Xavier Chauchet attend in-person the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting on November 10-14, 2021 in Washington DC (Press release, Light Chain Bioscience, NOV 8, 2021, View Source [SID1234594730]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Xavier will present our innovative and differentiating CD47xPD-L1 bispecific antibodies for a simultaneous blockade of PD-1/PD-L1 and CD47/SIRPa immune checkpoint axes, NI-2601 and NI-2901. The programs are currently in late discovery phase and clinical lead candidates have been identified.

The poster entitled "CD47xPD-L1 bispecific antibodies for cancer therapy" (#265) will be exposed and presented on Nov. 12 between 9:55-10:10 a.m., 12:40-14:10 p.m., 4:35-4:50 p.m. and 7:00-8:30 p.m. and available on the SITC (Free SITC Whitepaper) virtual meeting ePoster platform from 7 a.m. on Friday, Nov.12.